Europe sets a “decision date” for the fate of the “Pfizer”...

Europe sets a “decision date” for the fate of the “Pfizer”...
Europe sets a “decision date” for the fate of the “Pfizer”...
The agency indicated, in a statement, that on January 12, it would take a decision on approving an experimental vaccine For the emerging corona virus Developed by the company “Moderna”.

The agency responsible for regulating the entry of drugs into European Union, That it has already started a “renewed review” of the vaccine based on laboratory data provided by “Moderna”, previously, and will now evaluate data on the effectiveness of the vaccine in provoking an immune response and its efficacy for use throughout Europe.

The agency said that “if the results are strong enough to confirm quality, safety and efficacy,” then it can approve the vaccine at the meeting scheduled for January 12th.

Available before the end of the year

And two companies advanced. “PfizerAnd Biontech has applied for a license to market their vaccine against the emerging corona virus in Europe.

The two groups said in a statement that, on Monday, they had requested from European Medicines Agency “To obtain a conditional license to market” their vaccine after tests showed it was 95 percent effective against Covid-19.

The statement added that the vaccine “will be available in Europe before the end of 2020” in case he obtains the necessary license, according to “AFP.”

“Pfizer” and its German partner, “Biontech”, announced a few days ago that the results of the final experiments showed that their vaccine was effective in preventing Covid-19 by 95 percent without any safety concerns.

The companies expect the US Food and Drug Administration to grant approval for emergency use by mid-December.

Pfizer said it expects to have 50 million vaccine doses ready this year, enough to protect 25 million people.

Pfizer has an agreement to sell 100 million doses of its vaccine to the United States government, and gives it the option to purchase 500 million additional doses. The company is also in talks with other governments, including the European Union, about similar deals.

The two companies ’vaccine uses” mRNA “or” ribonucleic acid “technology, as it programs human cells to produce copies of a part of the virus, with the aim of stimulating the immune system to attack in the event that the real virus enters the body.

The announcement of the license application for the “Pfizer” vaccine against Covid-19 in Europe came after American media reported that the first shipments of the “Pfizer” vaccine arrived in the United States from the company’s laboratory in Belgium.

These were the details of the news Europe sets a “decision date” for the fate of the “Pfizer”... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at eg24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Biden faces challenge in guiding America past Trump era
NEXT India's foreign ministry launches app to connect to citizens abroad